Medtronic's Intrepid Valve Eliminates Mitral Regurgitation At 30 Days, Study Shows

Medtronic plc MDT announced early data for its self-expanding Intrepid transcatheter mitral valve replacement (TMVR) system for mitral valve regurgitation (MR) utilizing the transfemoral access route.
Data from the first 15 patients enrolled in an Early Feasibility Study of the Intrepid Transfemoral System showed 100% survival and no stroke, a median procedure time of 46 minutes, and none/trace MR in all implanted patients at 30 days.
The data were published simultaneously in the American College of Cardiology (JACC): Cardiovascular Intervention.
Mitral regurgitation (MR) occurs when blood flows backward through the mitral valve and into the atrium when the left ventricle contracts.
The Intrepid valve has been used to treat more than 350 patients as part of global clinical trials.
The Intrepid TMVR system is only available for investigational use, and it is not approved outside of clinical studies.
Related: Medtronic Touts 5-Year Data Of Self-Expanding TAVR Platform.
Price Action: MDT shares closed at $122.98 on Friday.

Momentum52.38

Growth43.19

Quality31.42

Value22.58

Short

Medium

Long